Oral Semaglutide and Retatrutide: What's New in GLP-1 for 2026

The pace of change in the GLP-1 field makes it worth a periodic catch-up. Nothing here is prescribing guidance — these are prescription medicines — but keeping current helps clinics answer the questions patients now arrive with.

The Move to Oral Formulations

Until recently, the most effective weight-management agents were injectables. That is changing. An oral form of semaglutide was approved for weight management in late 2025, and further oral options followed in 2026. For patients deterred by injections, oral delivery removes a significant barrier — though the gastrointestinal side-effect profile and the need for supervision remain.

Retatrutide: The Triple Agonist

The most watched pipeline agent is retatrutide, which adds a third mechanism (glucagon) to the GIP/GLP-1 combination seen in tirzepatide. In late-stage trials it has reported average weight loss in the region of 28% — a step beyond the roughly 21% associated with tirzepatide and 15% with semaglutide — with regulatory submission anticipated. If approved, it would raise the ceiling again.

Each Step Raises the Bar

A useful way to frame the trajectory: semaglutide (~15%) → dual-agonist tirzepatide (~21%) → triple-agonist retatrutide (~28%). Each new mechanism has pushed the average result higher. For aesthetics, this matters for one clear reason — larger, faster weight loss means more pronounced volume change in the face and body, and a greater role for restorative treatments afterward.

Beyond the Scale

The other shift is conceptual: GLP-1 medicines are increasingly studied and used as whole-body therapies, with attention to cardiovascular, metabolic-liver and joint outcomes rather than weight alone. Alongside this, muscle preservation has become a major research focus, since some of the weight lost is lean mass — a topic we cover separately in preserving muscle mass on GLP-1 therapy.

What It Means for a Clinic

Two practical implications. First, patients will increasingly ask about the newer and oral options — a clinic that can orient them (and refer to an appropriate prescriber) builds trust. Second, the aesthetic aftercare conversation becomes more, not less, relevant as the medicines get more powerful: more dramatic loss means more demand for volume restoration with biostimulators and fillers.

The Takeaway

2026's headlines are oral semaglutide and the higher-efficacy triple agonist retatrutide, within a broader shift toward whole-body benefit. As results deepen, so does the need for thoughtful aesthetic restoration afterward. For the fundamentals, start with how the GLP-1 options differ.